Pricing Log in Create free account
Friday 6 November 2026 Export RYTM’s income statement to Excel — free account

Rhythm Pharmaceuticals, Inc.

RYTM Healthcare Biotechnology

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.

Revenue
+79.6%
EPS
+26.9%
Free cash flow
+95.4%

Quarter to September 2026, against a year earlier

112.38 7.36 +7.01%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−31.6×
Dividend yield
—
F-score
6/9
Altman Z
15.89
Beneish M
−2.93
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings, changes and red flags

Red flags

  • Short cash runway

    Rhythm Pharmaceuticals, Inc.’s cash and short-term investments cover about 2.1 quarters of its operating cash burn

    10-Q filed · The filing · sec.gov

  • Material weakness

    Rhythm Pharmaceuticals, Inc.’s 10-K reports a material weakness in internal control over financial reporting

    In response to the identified material weakness above, we implemented measures designed to improve internal control over financial reporting to remediate the control deficiencies that led to our material weakness.

    10-K filed · The filing · sec.gov

  • Officer departure

    Rhythm Pharmaceuticals, Inc. reported the departure of an officer or director

    8-K filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 27 added · 44 removed · 49 modified
P2I1A: no comparison — low extraction confidence 		Short cash runway
8-K Nov 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 60 added · 23 removed · 32 modified
P2I1A: no comparison — low extraction confidence
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jun 24, 2026 5.07 Submission of matters to a vote of security holders
8-K Jun 13, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 1, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K Mar 26, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 19, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 16, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 2, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 62 added · 41 removed · 141 modified
1A: 15 added · 18 removed · 146 modified
7: 9 added · 20 removed · 43 modified
8-K Feb 26, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 9, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 16, 2025 5.02 Departure or appointment of directors or officers
8-K Dec 11, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 6, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 Material weakness
8-K Feb 26, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 10, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 5, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 22, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 7, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.